Welcome to our dedicated page for Black Diamond Therapeutics SEC filings (Ticker: BDTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Black Diamond Therapeutics, Inc. (NASDAQ: BDTX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Black Diamond is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, with a lead focus on silevertinib/BDTX-1535 in EGFR-mutant non-small cell lung cancer (NSCLC) and glioblastoma (GBM).
Through this page, users can review current and historical filings such as Forms 10-K and 10-Q, which describe the company’s research and development activities, clinical trial programs in NSCLC and GBM, and risk factors associated with developing MasterKey therapies. Form 8-K filings, including those announcing quarterly financial results and corporate updates, provide additional detail on cash position, operating expenses, and material agreements like the global licensing arrangement with Servier for BDTX-4933.
Investors can also reference registration statements, proxy materials, and, where applicable, insider transaction reports on Form 4 to better understand equity ownership and changes in holdings by officers, directors, and significant shareholders. These documents collectively outline how Black Diamond funds and prioritizes its development of brain-penetrant EGFR inhibitors and mutation-focused small molecules.
Stock Titan enhances this information with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly identify disclosures related to clinical milestones, partnerships, cash runway, and other factors relevant to BDTX. Real-time updates from EDGAR ensure that new Black Diamond Therapeutics filings appear promptly, while AI-generated overviews make complex oncology and biotechnology disclosures more accessible.
Black Diamond Therapeutics (BDTX) reported Q3 2025 results showing a net loss of
Cash, cash equivalents and investments totaled about
The Servier deal included a
Black Diamond Therapeutics (BDTX) furnished an 8-K announcing financial results for the three and nine months ended September 30, 2025. The company issued a press release with the details, which is included as Exhibit 99.1. The information was furnished, not filed, under Item 2.02.
Director Behbahani Ali received 4,291 shares of Black Diamond Therapeutics common stock on 09/19/2025 under the companys Fifth Amended and Restated Non-Employee Director Compensation Policy by electing stock in lieu of cash. The report shows a per-share price of $3.35 based on the closing market price on 09/18/2025. After the issuance, the Reporting Persons direct beneficial ownership is reported as 81,441 shares and indirect ownership is reported as 4,448,757 shares through NEA 16, with a disclaimer that the Reporting Person disclaims beneficial ownership of portions where no pecuniary interest exists. The Form 4 discloses the reporting relationship as a director and that the transaction code is an acquisition for director compensation.
Raman Prakash, a non-employee director of Black Diamond Therapeutics, Inc. (BDTX), elected to receive 3,843 shares of the issuer's common stock in lieu of cash for annual director compensation. The shares were issued on 09/19/2025 under the company’s Fifth Amended and Restated Non-Employee Director Compensation Policy. After the issuance, the reporting person beneficially owned 26,362 shares. The reported per-share price of $3.35 reflects the closing market price on 09/18/2025. The Form 4 was signed by an attorney-in-fact on 09/22/2025.
Director Ali Behbahani of Black Diamond Therapeutics reported acquiring 6,170 shares of common stock at $2.33 per share on June 20, 2025. The shares were issued as compensation for annual services as a non-employee director, in lieu of cash compensation under the company's Fifth Amended and Restated Non-Employee Director Compensation Policy.
Following the transaction, Behbahani directly owns 77,150 shares and indirectly controls 4,448,757 shares through NEA 16 GP, LLC, where he serves as a manager. The indirect ownership is through a complex structure involving NEA Partners 16, L.P. and New Enterprise Associates 16, L.P., though Behbahani disclaims beneficial ownership of these shares under Section 16 rules.
This Form 4 filing demonstrates continued insider engagement through equity-based compensation, with the director choosing stock over cash compensation, potentially indicating confidence in the company's future prospects.
Black Diamond Therapeutics Director Prakash Raman acquired 5,526 shares of common stock at $2.33 per share on June 20, 2025, bringing their total direct ownership to 22,519 shares.
Key details of the transaction:
- The shares were issued under the company's Fifth Amended and Restated Non-Employee Director Compensation Policy
- The acquisition represents an election to receive stock in lieu of cash compensation for annual services as a non-employee director
- The reported price is based on the closing market price of the company's common stock on June 18, 2025
- The transaction was reported via Form 4 filing, executed by Attorney-in-Fact Brent Hatzis-Schoch